SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glaxosmithkline Pharma trades in green post reporting Q4 numbers

17 Feb 2012 Evaluate

Glaxosmithkline Pharmaceuticals is currently trading at Rs 2090.00, up by 1.80 points or 0.09% from its previous closing of Rs 2088.20 on the BSE.

The scrip opened at Rs 2139.90 and has touched a high and low of Rs 2149.95 and Rs 2085.85 respectively. So far 2021 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 10 has touched a 52 week high of Rs 2475.00 on 14-Jun-2011 and a 52 week low of Rs 1830.00 on 20-Dec-2011.

Last one week high and low of the scrip stood at Rs 2149.95 and Rs 2030.00 respectively. The current market cap of the company is Rs 17719.87 crore.

The promoters holding in the company stood at 50.67% while Institutions and Non-Institutions held 32.66% and 16.67% respectively.

GlaxoSmithKline Pharmaceuticals has posted a rise of 18.18% in its net profit at Rs 136.74 crore for the quarter ended December 31, 2011 as compared to Rs 115.70 crore for the same quarter in the previous year. Total income has increased by 15.35% at Rs 577.60 crore for the quarter under review as compared to Rs 500.72 crore year ago.

GlaxoSmithKline Pharmaceuticals is one oldest pharmaceutical company in India. Internationally it has created many brands such as Ribena, Horlicks, Lucozade, Aquafresh, Sensodyne, Panadol, Tums and Zovirax, among others. It employs 5,000 people and has turnover of more than $1 billion in India.

Glaxosmithkline Phar Share Price

2419.10 12.85 (0.53%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×